Inhibitory effects of terrein on lung cancer cell metastasis and angiogenesis

Oncol Rep. 2021 Jun;45(6):94. doi: 10.3892/or.2021.8045. Epub 2021 Apr 13.

Abstract

Cancer metastasis is the leading cause of mortality in cancer patients. Over 70% of lung cancer patients are diagnosed at advanced or metastatic stages, and this results in an increased incidence of mortality. Terrein is a secondary bioactive fungal metabolite isolated from Aspergillus terreus. Numerous studies have demonstrated that terrein has anticancer properties, but in the present study, the cellular mechanisms underlying the inhibition of lung cancer cell metastasis by terrein was investigated for the first time. Using MTT assays, the cytotoxic effects of terrein were first examined in human lung cancer cells (A549 cells) and then compared with its cytotoxic effects in three noncancer control cell lines (Vero kidney, L6 skeletal muscle and H9C2 cardiomyoblast cells). The results indicated that terrein significantly reduced the viability of all these cells but exhibited a different level of toxicity in each cell type; these results revealed a specific concentration range in which the effect of terrein was specific to A549 cells. This significant cytotoxic effect of terrein in A549 cells was verified using LDH assays. It was then demonstrated that terrein attenuated the proliferation of A549 cells using IncuCyte image analysis. Regarding its antimetastatic effects, terrein significantly inhibited A549 cell adhesion, migration and invasion. In addition, terrein suppressed the angiogenic processes of A549 cells, including vascular endothelial growth factor (VEGF) secretion, capillary‑like tube formation and VEGF/VEGFR2 interaction. These phenomena were accompanied by reduced protein levels of integrins, FAK, and their downstream mediators (e.g., PI3K, AKT, mTORC1 and P70S6K). All these data indicated that terrein was able to inhibit all the major metastatic processes in human lung cancer cells, which is crucial for cancer treatment.

Keywords: terrein; non‑small cell lung cancer; migration; invasion; angiogenesis; metastasis.

MeSH terms

  • A549 Cells
  • Animals
  • Aspergillus / chemistry*
  • Carcinoma, Non-Small-Cell Lung / blood supply
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / secondary
  • Cell Adhesion / drug effects
  • Cell Movement / drug effects
  • Chlorocebus aethiops
  • Cyclopentanes / isolation & purification
  • Cyclopentanes / pharmacology*
  • Cyclopentanes / therapeutic use
  • Humans
  • Lung Neoplasms / blood supply
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Neovascularization, Pathologic / drug therapy*
  • Neovascularization, Pathologic / pathology
  • Vascular Endothelial Growth Factor A / metabolism
  • Vascular Endothelial Growth Factor Receptor-2 / metabolism
  • Vero Cells

Substances

  • Cyclopentanes
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • terrein
  • KDR protein, human
  • Vascular Endothelial Growth Factor Receptor-2

Supplementary concepts

  • Aspergillus terreus

Grants and funding

This work was supported by research grants from the Faculty of Medicine (grant nos. 140/2560 and 209/2562), Graduate School and The Strategic Wisdom and Research Institute, Srinakharinwirot University, Thailand, National Research Council of Thailand: NRCT (2562) and Canada-ASEAN Scholarships and Educational Exchanges for Development (2019–2020). Work in the GS lab was funded by the National Science and Engineering Research Council (NSERC), Canadian Institutes of Health Research (CIHR) and a Career Investigator Award from the Heart and Stroke Foundation.